

John M. Pagel, MD, PhD

Dr. Pagel is Chief of Hematologic Malignancies and the Director of Stem Cell Transplantation at Swedish Cancer Institute in Seattle, Washington. Dr. Pagel earned his BA in biology and his PhD in microbiology and molecular genetics from the University of California. He then received his medical degree from Boston University School of Medicine where he graduated magna cum laude. Following his residency in internal medicine at the University of California, San Francisco, he went on to do his oncology fellowship at the University of Washington. Dr. Pagel is also the recipient of numerous prestigious awards including the Damon Runyon Clinical Investigator Award, the Lymphoma Research Foundation Career Development Award, the American Society of Clinical Oncology Young Investigator Award and the American Society of Clinical Oncology Career Development Award. He has been the Principal Investigator on multiple awarded NIH grants including a K08, four RO1 grants and two R21 awards. Moreover, he has led projects on three major NIH Program Project grants for over a decade and serves as a Core Principal Investigator on two other Program Project Grants.

Dr. Pagel's research interests include the development and discovery of novel therapeutics for the treatment of blood cancers, including lymphomas and leukemias. His current research focuses on strategies for delivering innovative targeted immunotherapy agents to patients with hematologic malignancies. Prior to joining Swedish he was an Associate Professor of Medicine at the University of Washington in the Division of Oncology and an Associate Member at the Fred Hutchinson Cancer Research Center in Seattle. Dr. Pagel has mentored over 25 junior faculty members and fellows and has directly helped their successful achievement of several NIH grants including 6 with K08 awards and 2 with K23 awards. More than 10 fellows who Dr. Pagel directly mentored have gone to hold faculty positions at major institutions such as The Fred Hutchinson Cancer Research Center, Duke University, and Memorial Sloan Kettering Cancer Center. He has served as the principal investigator of numerous protocols and is also involved in several other ongoing clinical trials. His research has resulted in over 100 publications in peer-reviewed journals, including, but not limited to, *the New England Journal of Medicine*, *Blood*, *Journal of Clinical Oncology* and *Bone Marrow Transplantation*, as well as numerous abstracts of papers at national and international meetings.